Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
KalVista Pharmaceuticals recently announces Phase 3 KONFIDENT trial of Sebetralstat meets all primary and key secondary endpoints as first oral on-demand therapy for Hereditary Angioedema (HAE). HAE is a rare and potentially life-threatening genetic disease caused by low levels or dysfunction of the C1 inhibitor, associated with uncontrolled plasma kallikrein (PKa) activity and generation of bradykinin (BK).
Sebetralstat is an investigational novel, oral plasma kallikrein inhibitor with a favorable safety profile. It works by targeting the kallikrein–kinin system (KKS), reducing the activity of plasma kallikrein and blocking uncontrolled bradykinin release in HAE attack. The Phase 3 results also show rapid symptom relief in a broad HAE population.
Buscar 
+86 21 5895 0110 
